Leukemia Drug Shows Promise in Lewy Body Dementia

Nilotinib, a drug approved by the US Food and Drug Administration (FDA) to treat chronic myeloid leukemia, improved biomarkers and cognitive outcomes in patients with dementia with Lewy bodies (DLB) in a phase 2 randomized, double-blind, placebo-controlled trial.  The findings align with an earlier study that showed possible disease-modifying effects of nilotinib in patients with ...

https://teach.coursemateai.com/home/course/get-it-done/163 
Get In Touch

Cape Breton, NS

+012 345 67890

Chris@websurfer.ca

Follow Us
Flickr Photos

Copyright © 2023 cape-breton.com. Toady's News. All Rights Reserved